Trials Sponsors Conditions Drugs Pricing

Conditions

Diagnosis, Dual (Psychiatry)

Keywords

Psychiatric Dual DiagnosisIntegrated AttentionProgram

Outcome Measures

Primary Outcomes (6)

Stages of Change Readiness
Assessed by Questionnaire SOCRATES 8D
12 months
Insight
Assessed by Scale Unawareness of Mental Disorders (SUMD)
12 months
Medication Adherence
Assessed by Medication Adherence Scale (MMAS-8)
12 months
Therapeutic Alliance
Assessed by Working Alliance Inventory in patients and therapist (WAI-P and WAI-T)
2-3 months
Anxiety
Assessed by Hamilton Anxiety Rating Scale (HARS)
12 months
Hopelessness
Assessed by Hopelessness Scale (HS)

Secondary Outcomes (4)

Containments methods
2-3 months
Drug use change
12 months
Hospital readmissions
12 months
Dual diagnosis knowledge
12 months

Study Arms (2)

Intervention group

EXPERIMENTAL

The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.

Behavioral: D-AIP

Control group

NO INTERVENTION

The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication

Interventions

D-AIPBehavioral

Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety

Intervention group

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Inpatients diagnosed with some serious mental illness of the following:
Inpatients with diagnosis of schizophrenia

Sponsors & Collaborators

Cardenal Herrera University
Otherlead

MeSH Terms

Conditions

Disease

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Montse Cañabate, Dra.
Cardenal Herrera University
PRINCIPAL INVESTIGATOR

Central Study Contacts

Montse Cañabate, Dra.

CONTACT

+34-601-209-435 montserrat.canabate@uchceu.es

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

February 20, 2020

First Posted

June 23, 2020

Study Start

September 1, 2020

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Dual Integrated Attention Program (DAIP) in People With Severe Dual Diagnosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (6)

Secondary Outcomes (4)

Study Arms (2)

Intervention group

Control group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (6)

Secondary Outcomes (4)

Study Arms (2)

Intervention group

Control group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record